Dynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation using Pharmacokinetics

Abstract Preoperative renal tumor subtype differentiation is important for radiology and urology in clinical practice. Pharmacokinetic data (K trans & V e, etc.) derived from dynamic contrast-enhanced MRI (DCE-MRI) have been used to investigate tumor vessel permeability. In this prospective stud...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hai-yi Wang, Zi-hua Su, Xiao Xu, Ning Huang, Zhi-peng Sun, Ying-wei Wang, Lu Li, Ai-tao Guo, Xin Chen, Xin Ma, Lin Ma, Hui-yi Ye
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/aa27053d5f964a738b5cd351a1f8710c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aa27053d5f964a738b5cd351a1f8710c
record_format	dspace
spelling	oai:doaj.org-article:aa27053d5f964a738b5cd351a1f8710c2021-12-02T16:06:46ZDynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation using Pharmacokinetics10.1038/s41598-017-03376-72045-2322https://doaj.org/article/aa27053d5f964a738b5cd351a1f8710c2017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-03376-7https://doaj.org/toc/2045-2322Abstract Preoperative renal tumor subtype differentiation is important for radiology and urology in clinical practice. Pharmacokinetic data (K trans & V e, etc.) derived from dynamic contrast-enhanced MRI (DCE-MRI) have been used to investigate tumor vessel permeability. In this prospective study on DCE-MRI pharmacokinetic studies, we enrolled patients with five common renal tumor subtypes: clear cell renal cell carcinoma (ccRCC; n = 65), papillary renal cell carcinoma (pRCC; n = 12), chromophobic renal cell carcinoma (cRCC; n = 9), uroepithelial carcinoma (UEC; n = 14), and fat-poor angiomyolipoma (fpAML; n = 10). The results show that K trans of ccRCC, pRCC, cRCC, UEC and fpAML (0.459 ± 0.190 min−1, 0.206 ± 0.127 min−1, 0.311 ± 0.111 min−1, 0.235 ± 0.116 min−1, 0.511 ± 0.159 min−1, respectively) were different, but V e was not. K trans could distinguish ccRCC from non-ccRCC (pRCC & cRCC) with a sensitivity of 76.9% and a specificity of 71.4%, respectively, as well as to differentiate fpAML from non-ccRCC with a sensitivity of 100% and a specificity of 76.2%, respectively. Our findings suggest that DCE-MRI pharmacokinetics are promising for differential diagnosis of renal tumors, especially for RCC subtype characterization and differentiation between fpAML and non-ccRCC, which may facilitate the treatment of renal tumors.Hai-yi WangZi-hua SuXiao XuNing HuangZhi-peng SunYing-wei WangLu LiAi-tao GuoXin ChenXin MaLin MaHui-yi YeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hai-yi Wang Zi-hua Su Xiao Xu Ning Huang Zhi-peng Sun Ying-wei Wang Lu Li Ai-tao Guo Xin Chen Xin Ma Lin Ma Hui-yi Ye Dynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation using Pharmacokinetics
description	Abstract Preoperative renal tumor subtype differentiation is important for radiology and urology in clinical practice. Pharmacokinetic data (K trans & V e, etc.) derived from dynamic contrast-enhanced MRI (DCE-MRI) have been used to investigate tumor vessel permeability. In this prospective study on DCE-MRI pharmacokinetic studies, we enrolled patients with five common renal tumor subtypes: clear cell renal cell carcinoma (ccRCC; n = 65), papillary renal cell carcinoma (pRCC; n = 12), chromophobic renal cell carcinoma (cRCC; n = 9), uroepithelial carcinoma (UEC; n = 14), and fat-poor angiomyolipoma (fpAML; n = 10). The results show that K trans of ccRCC, pRCC, cRCC, UEC and fpAML (0.459 ± 0.190 min−1, 0.206 ± 0.127 min−1, 0.311 ± 0.111 min−1, 0.235 ± 0.116 min−1, 0.511 ± 0.159 min−1, respectively) were different, but V e was not. K trans could distinguish ccRCC from non-ccRCC (pRCC & cRCC) with a sensitivity of 76.9% and a specificity of 71.4%, respectively, as well as to differentiate fpAML from non-ccRCC with a sensitivity of 100% and a specificity of 76.2%, respectively. Our findings suggest that DCE-MRI pharmacokinetics are promising for differential diagnosis of renal tumors, especially for RCC subtype characterization and differentiation between fpAML and non-ccRCC, which may facilitate the treatment of renal tumors.
format	article
author	Hai-yi Wang Zi-hua Su Xiao Xu Ning Huang Zhi-peng Sun Ying-wei Wang Lu Li Ai-tao Guo Xin Chen Xin Ma Lin Ma Hui-yi Ye
author_facet	Hai-yi Wang Zi-hua Su Xiao Xu Ning Huang Zhi-peng Sun Ying-wei Wang Lu Li Ai-tao Guo Xin Chen Xin Ma Lin Ma Hui-yi Ye
author_sort	Hai-yi Wang
title	Dynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation using Pharmacokinetics
title_short	Dynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation using Pharmacokinetics
title_full	Dynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation using Pharmacokinetics
title_fullStr	Dynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation using Pharmacokinetics
title_full_unstemmed	Dynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation using Pharmacokinetics
title_sort	dynamic contrast-enhanced mri in renal tumors: common subtype differentiation using pharmacokinetics
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/aa27053d5f964a738b5cd351a1f8710c
work_keys_str_mv	AT haiyiwang dynamiccontrastenhancedmriinrenaltumorscommonsubtypedifferentiationusingpharmacokinetics AT zihuasu dynamiccontrastenhancedmriinrenaltumorscommonsubtypedifferentiationusingpharmacokinetics AT xiaoxu dynamiccontrastenhancedmriinrenaltumorscommonsubtypedifferentiationusingpharmacokinetics AT ninghuang dynamiccontrastenhancedmriinrenaltumorscommonsubtypedifferentiationusingpharmacokinetics AT zhipengsun dynamiccontrastenhancedmriinrenaltumorscommonsubtypedifferentiationusingpharmacokinetics AT yingweiwang dynamiccontrastenhancedmriinrenaltumorscommonsubtypedifferentiationusingpharmacokinetics AT luli dynamiccontrastenhancedmriinrenaltumorscommonsubtypedifferentiationusingpharmacokinetics AT aitaoguo dynamiccontrastenhancedmriinrenaltumorscommonsubtypedifferentiationusingpharmacokinetics AT xinchen dynamiccontrastenhancedmriinrenaltumorscommonsubtypedifferentiationusingpharmacokinetics AT xinma dynamiccontrastenhancedmriinrenaltumorscommonsubtypedifferentiationusingpharmacokinetics AT linma dynamiccontrastenhancedmriinrenaltumorscommonsubtypedifferentiationusingpharmacokinetics AT huiyiye dynamiccontrastenhancedmriinrenaltumorscommonsubtypedifferentiationusingpharmacokinetics
_version_	1718384862640996352

Dynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation using Pharmacokinetics

Ejemplares similares